Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

Kimberley Hanson; Stephen D. Robinson; Karamallah Al-Yousuf; Adam E. Hendry; Darren W. Sexton; Victoria Sherwood; Grant N. Wheeler

doi:10.18632/oncotarget.26415

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

PDF | How to cite

Oncotarget. 2018; 9:36645-36645. https://doi.org/10.18632/oncotarget.26415

Metrics: PDF 1540 views | ?

Kimberley Hanson¹, Stephen D. Robinson¹, Karamallah Al-Yousuf^2,3, Adam E. Hendry¹, Darren W. Sexton^4,5, Victoria Sherwood^2,3 and Grant N. Wheeler¹

¹ School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
² School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
³ Present address: Division of Cancer Sciences, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
⁴ Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
⁵ Present address: Pharmacy and Biomedical Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK

Published: November 27, 2018

This article has been corrected: The correct Author name is given below:

Stephen D. Robinson

Original article: Oncotarget. 2018; 9:3815-3829. DOI: https://doi.org/10.18632/oncotarget.23378.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26415

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth